The FDA has strengthened warning labels on Amgen's anemia drugs Aranesp and Epogen, as well as Johnson & Johnson's Procrit, to advise of a link to tumor growth and lowered survival rates in cancer patients. The drugmakers say that the FDA's warning is specific to a certain use of the drug and that it is safe for other cancer and kidney patients.

Related Summaries